首页> 外文期刊>British Journal of Pharmacology >Lack of beneficial effects of the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats
【24h】

Lack of beneficial effects of the NO-donor, molsidomine, in the L-NAME-induced pre-eclamptic syndrome in pregnant rats

机译:NO供体莫斯多明在L-NAME诱发的先兆子痫综合征中缺乏有益的作用

获取原文
获取原文并翻译 | 示例
           

摘要

1 In pregnant rats, chronic NO-synthase inhibition induces the development of a pre-eclamptic syndrome, characterized by an increase in maternal blood pressure, a loss of vascular refractoriness to pressor stimuli, a reduction in litter size and a decrease in pups (and maternal) weight. We investigated whether a NO-donor, molsidomine, administered during NO synthase inhibition, could restore a normal pregnancy. 2 Pregnant rats were given daily, starting from day 14 of gestation, saline (controls), or L-NAME (50 mg kg~(-1) d~(-1)), or molsidomine (15 or 30 mg kg~(-1) d~(-1)), or the L-NAME + molsidomine combinations. Maternal blood pressure and body weight, litter size, pups weight and vascular reactivity to pressor stimuli (angiotensin II, noradrenaline, electrical stimulation of the spinal cord) were investigated. 3 L-NAME alone, as compared to controls, increased maternal blood pressure, reduced litter size (-59%), increased foetal reabsorptions ( +625%) and decreased foetal weight (-10%). Vascular reactivity to pressor stimuli was enhanced. 4 Molsidomine alone, as compared to controls, dose-dependently decreased maternal blood pressure but had no effect on vascular reactivity and, whatever the dose, on foetal outcome. 5 The L-NAME-molsidomine combinations dose (of molsidomine)-dependently limited the rise in maternal blood pressure induced by L-NAME alone but unexpectedly, dose-dependently and significantly worsened pregnancy evolution, e.g., at 30 mg kg~(-1)d~(-1): litter size ( - 80%), foetal reabsorptions (+1025%), foetal weight (-24%). Vascular reactivity to pressor stimuli was paradoxically further enhanced. 6 Thus, in a chronic NO deprivation-induced model of pre-eclampsia in rats, molsidomine, possibly because of its hypotensive action, worsens the foetal outcome, which questions the usefulness of NO-donors in pre-eclamptic women.
机译:1在怀孕的大鼠中,慢性NO合酶抑制导致先兆子痫综合征的发展,其特征是母体血压升高,对升压刺激的血管耐火性降低,产仔数减少和幼崽的减少(和孕妇)的体重。我们调查了在NO合酶抑制期间给予的NO供体莫西敏是否可以恢复正常妊娠。从妊娠第14天开始每天给予2只妊娠大鼠,生理盐水(对照组)或L-NAME(50 mg kg〜(-1)d〜(-1))或吗啡胺(15或30 mg kg〜( -1)d〜(-1))或L-NAME + molsidomine的组合。研究了孕妇的血压和体重,窝产仔数,幼犬体重以及对加压物(血管紧张素II,去甲肾上腺素,脊髓电刺激)的血管反应性。与对照组相比,单独使用3 L-NAME会增加孕妇血压,减少产仔数(-59%),增加胎儿重吸收(+ 625%)和减少胎儿体重(-10%)。对加压刺激的血管反应性增强。 [4]与对照组相比,单独的莫西多明单独剂量依赖性地降低了孕产妇的血压,但对血管反应性和胎儿剂量均无影响。 5 L-NAME-molsidomine组合剂量(molsidomine的剂量)依赖性地限制了仅由L-NAME诱导的孕产妇血压的升高,但出乎意料的是,剂量依赖性地并显着恶化了妊娠的发展,例如30 mg kg〜(-1 d〜(-1):产仔数(-80%),胎儿重吸收(+ 1025%),胎儿体重(-24%)。加压刺激的血管反应性反常地进一步增强。 [6]因此,在大鼠慢性先天性NO剥夺诱导的先兆子痫模型中,莫斯多明可能由于其降压作用而使胎儿结局恶化,这对先兆子痫前期妇女使用NO供体的有效性提出了质疑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号